Mary L Disis|John T Slattery - JoVE Visualize

Showing results (151-160 of 209) with videos related to

Pageof 21

Sort By:

Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 5, 2003

Identification of tumor-specific antibodies in patients with breast cancer vaccinated with gene-modified allogeneic tumor cellsAnnemieke Dols, Sybren L Meijer, Hong-Ming Hu, et al.

Breast Cancer Research and Treatment|August 9, 2014

Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic miceEun-Young Gil, Uk-Hyun Jo, Hye Jin Lee, et al.

Blood|October 31, 2002

Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantationGeorge B McDonald, John T Slattery, Michelle E Bouvier, et al.

Clinical Pharmacology and Therapeutics|September 13, 2005

Metabolism-based cyclophosphamide dosing for hematopoietic cell transplantGeorge B McDonald, Jeannine S McCune, Ami Batchelder, et al.

Journal of Immunological Methods|December 13, 2005

Maximizing the retention of antigen specific lymphocyte function after cryopreservationMary L Disis, Corazon dela Rosa, Vivian Goodell, et al.

Gynecologic Oncology|January 17, 2017

Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancerJohn B Liao, Ron E Swensen, Kelsie J Ovenell, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2016

Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHNLaura Q M Chow, Chihiro Morishima, Keith D Eaton, et al.

Proceedings of the National Academy of Sciences of the United States of America|September 18, 2016

Leveraging premalignant biology for immune-based cancer preventionAvrum Spira, Mary L Disis, John T Schiller, et al.

Journal of Immunology (Baltimore, Md. : 1950)|August 7, 2007

Functional T cell responses to tumor antigens in breast cancer patients have a distinct phenotype and cytokine signatureMargaret Inokuma, Corazon dela Rosa, Charles Schmitt, et al.

Evaluation & the Health Professions|September 26, 2013

Expanding assessments of translational research programs: supplementing metrics with value judgmentsCraig S Scott, Pamela R Nagasawa, Neil F Abernethy, et al.

Pageof 21

Showing results (151-160 of 209) with videos related to

Sort By:

Pageof 21

Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 5, 2003

Identification of tumor-specific antibodies in patients with breast cancer vaccinated with gene-modified allogeneic tumor cellsAnnemieke Dols, Sybren L Meijer, Hong-Ming Hu, et al.

Breast Cancer Research and Treatment|August 9, 2014

Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic miceEun-Young Gil, Uk-Hyun Jo, Hye Jin Lee, et al.

Blood|October 31, 2002

Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantationGeorge B McDonald, John T Slattery, Michelle E Bouvier, et al.

Clinical Pharmacology and Therapeutics|September 13, 2005

Metabolism-based cyclophosphamide dosing for hematopoietic cell transplantGeorge B McDonald, Jeannine S McCune, Ami Batchelder, et al.

Journal of Immunological Methods|December 13, 2005

Maximizing the retention of antigen specific lymphocyte function after cryopreservationMary L Disis, Corazon dela Rosa, Vivian Goodell, et al.

Gynecologic Oncology|January 17, 2017

Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancerJohn B Liao, Ron E Swensen, Kelsie J Ovenell, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2016

Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHNLaura Q M Chow, Chihiro Morishima, Keith D Eaton, et al.

Proceedings of the National Academy of Sciences of the United States of America|September 18, 2016

Leveraging premalignant biology for immune-based cancer preventionAvrum Spira, Mary L Disis, John T Schiller, et al.

Journal of Immunology (Baltimore, Md. : 1950)|August 7, 2007

Functional T cell responses to tumor antigens in breast cancer patients have a distinct phenotype and cytokine signatureMargaret Inokuma, Corazon dela Rosa, Charles Schmitt, et al.

Evaluation & the Health Professions|September 26, 2013

Expanding assessments of translational research programs: supplementing metrics with value judgmentsCraig S Scott, Pamela R Nagasawa, Neil F Abernethy, et al.

Pageof 21